Clinical trials · Dallas–Fort Worth, TX
Advanced or Metastatic Solid Tumors clinical trials in Dallas–Fort Worth
We’re tracking 301 recruiting advanced or metastatic solid tumors studies with a site in or near Dallas–Fort Worth — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Dallas–Fort Worth
- NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Dallas, TexasAges 18 years+ - NCT05503797RecruitingPhase 2
Study of FORE8394 for cancers with BRAF changes
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Dallas, TexasAges 8 years+ - NCT06943755RecruitingPhase 2/Phase 3
Zanzalintinib vs Everolimus for Neuroendocrine Tumors
This trial compares a new targeted therapy (zanzalintinib) with an existing drug (everolimus) for people with advanced neuroendocrine tumors (NETs). It aims to see which treatment works better and may offer a new option for patients whose cancer has grown despite previous treatments.
Dallas, TexasAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Dallas, TexasAges 18 years+ - NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Dallas, TexasAges 18 years+ - NCT05948865RecruitingPhase 1
Early trial drug for advanced solid tumors
This Phase 1 study tests CPO301 in adults with advanced or metastatic solid tumors that have worsened or cannot be treated with standard options. It aims to find the safest dose and understand how the treatment affects tumors, especially in certain lung cancer groups.
Dallas, TexasAges 18 years+ - NCT06350097RecruitingPhase 3
Osimertinib with or without datopotamab deruxtecan for first-line EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (osimertinib plus datopotamab deruxtecan) against osimertinib alone in patients with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It is for people with advanced or recurrent disease who have not yet received systemic treatment.
Dallas, TexasAges 18 years+ - NCT07659821Recruiting
Nutrition and wellness study for moms and babies
This study offers food kits and nutrition guidance to pregnant women to help support their health and their baby's wellness. You may be eligible if you are in early pregnancy (7–12 weeks) and live in the Dallas-Fort Worth or College Station area.
Dallas, TexasAges 18–45 - NCT06515990RecruitingPhase 1/Phase 2
DM005 for Advanced Solid Tumors
This study tests a new drug called DM005 for people with advanced solid tumors (like lung, stomach, colon, liver, pancreas, or head and neck cancer) that have not responded to or can't tolerate standard treatments. The goal is to see if DM005 is safe and how well it works.
Dallas, TexasAges 18 years+ - NCT06234098RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug called AT-1965 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can shrink tumors.
Dallas, TexasAges 18 years+ - NCT05861895RecruitingPhase 1
Study drug HF158K1 for HER2-positive advanced solid tumors
This Phase 1 trial tests HF158K1 in people with advanced solid tumors that have HER2 protein. It aims to see if the drug can be given safely and learn how it works in people whose cancer shows HER2 on tumor testing.
Dallas, TexasAges 18–75 - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Dallas, TexasAges 18 years+ - NCT07038343RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial tests a new drug called AVZO-1418, either alone or with other treatments, for people with advanced solid tumors that have spread or cannot be removed. The goal is to see if the drug is safe and effective against certain types of cancer.
Dallas, TexasAges 18–75 - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Dallas, TexasAges 18 years+ - NCT07265674RecruitingPhase 3
Study of nanvuranlat for advanced bile duct cancer
This study tests a new drug called nanvuranlat for people with advanced bile duct cancer that has gotten worse after platinum-based chemotherapy. It compares nanvuranlat with the doctor's choice of standard treatments to see which works better.
Dallas, TexasAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Dallas, TexasAges 18 years+ - NCT06128551RecruitingPhase 1/Phase 2
Testing two targeted drugs for KRAS G12C advanced cancer
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
Dallas, TexasAges 18 years+ - NCT06129864RecruitingPhase 3
Study of Volrustomig for advanced head and neck cancer after chemoradiation
This trial tests a new drug called volrustomig (MEDI5752) for people with advanced head and neck cancer that was not removed by surgery and has been treated with chemoradiation. The goal is to see if the drug can help prevent the cancer from coming back.
Dallas, TexasAges 18–130 - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Dallas, TexasAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Dallas, TexasAges Any age - NCT06467357RecruitingPhase 3
A study of T-DXd and rilvegostomig for HER2-positive bile duct cancer
This trial tests a new combination of two drugs (T-DXd and rilvegostomig) for people with advanced bile duct cancer that has not been treated before. The cancer must have high levels of a protein called HER2. This study compares the new drugs to standard treatments.
Dallas, TexasAges 18–99 - NCT07544654RecruitingPhase 3
Study comparing obrixtamig plus chemotherapy for advanced neuroendocrine cancer
This trial tests a new drug called obrixtamig combined with standard chemotherapy for advanced neuroendocrine cancer (a rare type of cancer). You'd receive one cycle of standard chemotherapy first, then be randomly assigned to either continue with the new drug plus chemotherapy or standard chemotherapy alone.
Dallas, TexasAges 18 years+ - NCT05361720RecruitingPhase 2
Genetic test to match treatment for advanced kidney cancer
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Dallas, TexasAges 18 years+ - NCT07612189RecruitingPhase 1
Testing NEOK002 for Advanced Solid Tumors
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
Dallas, TexasAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Dallas–Fort Worth, TX
We’ll email you when one opens near Dallas–Fort Worth, TX — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Dallas–Fort Worth
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Mary Crowley Cancer Research · 6 studies
- University of Texas Southwestern Medical Center · 6 studies
- NEXT Oncology · 4 studies
- Research Site · 3 studies
- Baylor University Medical Center · 2 studies
- Avenzo Therapeutics Recruiting Site
- Baylor Scott & White Research Institute
- CBCC Global Research
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in Texas.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Dallas–Fort Worth?
- Yes. We're currently tracking 301 recruiting advanced or metastatic solid tumors studies with a site near Dallas–Fort Worth, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Dallas–Fort Worth?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Dallas–Fort Worth to take part?
- Not necessarily. These studies have a site near Dallas–Fort Worth, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Dallas–Fort Worth regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.